Biochemical approaches to the combination chemotherapy of colon cancer

Sartorelli, Alan C.; Shansky, Charles W.; Rosman, Martin

doi:10.1002/1097-0142(197512)36:6<2445::aid-cncr2820360628>3.0.co;2-a

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thoughtful studies by Sartorelli et al . 4 , 5 , Darnowski and Handschumacher 6 , and Damon and Cadman 7 emphasized the importance of targeting the rate-limiting steps in the biochemical reactions and identifying the optimal sequence of drug exposure. Mayer and Janoff 8 illustrated the potential importance of maintaining constant ratios of the individual drugs whenever possible in the tumor and elsewhere.…”

Section: Theoretical Approaches To Discovering Cancer Drug Combinatiomentioning

confidence: 99%

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches

Lazo

2018

F1000Res

View full text Add to dashboard Cite

Cancer drug discoverers and developers are blessed and cursed with a plethora of drug targets in the tumor cells themselves and the surrounding stromal elements. This bounty of targets has, at least in part, inspired the rapid increase in the number of clinically available small-molecule, biological, and cellular therapies for solid and hematological malignancies. Among the most challenging questions in cancer therapeutics, especially for small molecules, is how to approach loss-of-function gene mutations or deletions that encode tumor suppressors. A second mounting question is what are the optimal drug combinations. This article will briefly review the recent advances in exploiting in vitro and in vivo synthetic lethal screens to expose cancer pharmacological targets with the goal of developing new drug combinations.

show abstract

Section: Theoretical Approaches To Discovering Cancer Drug Combinatiomentioning

confidence: 99%

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches

Lazo

2018

F1000Res

View full text Add to dashboard Cite

show abstract

An evaluation of markers in the early detection of large bowel cancer

Schwartz¹

1977

Cancer

View full text Add to dashboard Cite

In colon cancer biologic markers have been successfully utilized to follow the course of disease, to evaluate response to therapy, and to predict recurrence. With the exception of occult blood measurements, there has been little success in adopting markers to early diagnosis. The role of CEA in predicting the course of the disease is considered, as well as the utility of combining serum enzyme measurements and carcinoembryonic antigen (CEA) assays for these purposes. Aryl sulfatase B has been correlated to the stage of the disease, and enzymes involved in the metabolism of glycoproteins (sialyltransferase and glucosyltransferase) may be of importance in monitoring colon cancer. Polyamines have been observed in blood and urine of patients with a variety of cancers and their presence during therapy in increased amounts may reflect cancer cell death as well as tumor growth. Their use in diagnosis and chemo‐therapeutic monitoring in colon cancer has not yet been established. Another area of possible use of biologic markers is their measurement in colon washings. This is discussed in regard to the assay of CEA and enzymes in colonic lavage.

show abstract

Methyl‐CCNU, 6‐Thioguanine, and 5‐fluorouracil in advanced colorectal cancer

Aroney

Dalley

Chan

et al. 1981

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Consecutive studies were undertaken in advanced colorectal adenocarcinoma, comparing two different schedules of the combination methyl-CCNU, 6-thioguanine, and 5-fluorouracil in 89 patients. The two schedules exhibited similar efficacies, with a combined complete and partial remission rate of 17%, a median response duration of 36+ weeks, and a median survival of 53+ weeks. Significant symptomatic benefit was seen in 52% of patients. Toxicity was predominantly hemopoietic and gastrointestinal, being acceptable overall, with only minor qualitative differences between the two protocols. These triple-drug regimens exhibit response rates and survival patterns comparable with those reported for other multidrug combinations and some single agents. It would appear that major improvements in the management of advanced-stage disease must await the availability of more efficacious agents used alone or in combination.

show abstract

Biochemical approaches to the combination chemotherapy of colon cancer

Cited by 4 publications

References 8 publications

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches

An evaluation of markers in the early detection of large bowel cancer

Methyl‐CCNU, 6‐Thioguanine, and 5‐fluorouracil in advanced colorectal cancer

Contact Info

Product

Resources

About